Joyvie Health Raises $1.04M to Reimagine Incontinence Care

Jan de Vries · 2026-06-05

UK-based Joyvie Health just closed its pre-Seed funding round, pulling in $1.04 million for a fresh take on continence underwear. The product is built from scratch to cut stool-to-skin contact, protect skin health, and lighten the load for caregivers. The funding combines an Innovate UK grant with investments from HERmesa Angels, SyndicateRoom, Lavender Ventures, and a few individual angel investors. ### A Mission Born from Heartbreak “Products designed for care should never cause harm. That’s not a vision statement. It’s the reason this company exists,” says Zoe Robson, founder and CEO of Joyvie Health. Zoe’s father, Fred, was 77, fit, and sharp-minded when he got a late-stage pancreatic cancer diagnosis on Christmas Eve 2024. Eleven weeks later, he was gone. In those weeks, Fred lost bowel control and had to wear a nappy. Feces trapped against skin breaks it down—moisture, pathogens, and pH imbalance causing damage that never fully heals. His skin broke down, and his dignity slipped away with every change. Ruth, Fred’s wife and primary caregiver, carried an invisible, crushing burden. “My parents didn’t deserve that,” says Zoe. “They were both at their most vulnerable—and the product meant to help them was making it worse. The skin breakdown, the shame, the loss of dignity, the weight on my mom. It wasn’t from lack of care. It’s a design failure.”  ### How Joyvie’s Design Breaks the Cycle The company is on a mission to end the silent humiliation of fecal incontinence (FI), a condition affecting an estimated 656 million people globally. Yet the most common non-invasive solution—nappies and pads—hasn’t changed in decades. Where existing products trap stool against the skin, Joyvie’s underwear contains it in a disposable pouch right after excretion. This cuts skin contact by roughly 90% and speeds up changes by about 70%, according to early testing. The result? Less skin damage, more dignity, and less time spent on cleanup. ### A Big Year for European HealthTech Joyvie’s round sits alongside a wave of HealthTech funding across the UK and Europe in 2026. In the UK alone: - Semble raised $40.3 million for its healthcare management platform - Evaro secured $24.4 million to expand NHS-licensed health services - JAAQ closed $17.4 million for enterprise partnerships - Calibre emerged from stealth with $3.2 million for health analytics - Nul raised $975,000 for its alcohol-dependence care platform Elsewhere in Europe, Recare in Berlin pulled in up to $42.9 million for its AI hospital platform; Patronus raised $12.8 million for a senior-friendly smartwatch; Tucuvi scored $19.7 million for voice-AI nursing automation; Ditto in Rotterdam raised $8.8 million for patient-friendly medical info; ShanX Medtech secured $27.8 million for antimicrobial-resistance diagnostics; and MedVasc raised $2.5 million for its anesthesia catheter. All told, these rounds add up to over $201 million in related 2026 HealthTech funding. ### Investors See a Ripe Market “At Lavender Ventures, we are committed to backing founders addressing large, underserved markets with innovative solutions that can meaningfully improve people’s lives,” says Gail Armstrong of Lavender Ventures. “We believe the market is ripe for innovation, and Joyvie’s approach has the potential to deliver significant benefits not only for individuals, but also for carers, healthcare systems, and the environment.” ### The Bottom Line Joyvie Health isn’t just launching a product. It’s tackling a problem that’s been ignored for too long—one that affects millions and robs people of dignity. With a design that actually works differently, and funding that proves investors believe in the vision, this is a company worth watching.